Board director & advisor · Arvita Tripati
I help boards see the risks that sit between product, regulation, AI, quality, security, and commercial adoption before they become missed quarters, stalled deals, diligence issues, or failed implementations.
18+ years as an operator in regulated healthtech and AI, including 5+ as VP. 30+ regulated AI-enabled products.
The board gap
Boards hold finance, legal, clinical, and industry experience. Few hold someone who can tell whether the AI in the product creates clinical, regulatory, and financial exposure at once, and whether anyone has documented what happens when it fails.
The question that separates real governance from performing it: if the model fails in production on a Tuesday morning, what is the documented response, and when was it last tested? Asked early, that question is the difference between a clean diligence and a stalled exit.
The hardest board question in any AI or data company isn't whether the model works. It's whether the organization can deploy it in a way enterprise buyers trust and regulators accept. I help boards see whether the AI story is a real commercial asset or an unmanaged liability.
Interest, pilots, and early validation rarely convert to scalable contracts on their own. I help boards and CEOs understand what has to change for a promising product to become something enterprise buyers adopt, implement, renew, and expand.
Serious buyers run stress tests: quality maturity, manufacturing controls, regulatory defensibility, operational reliability, security posture. I help technical companies understand whether they're ready for the buyers, audits, workflows, and operational demands that come with scale. This maps as cleanly to robotics, manufacturing, capital equipment, and chemicals as it does to healthcare.
Boards often hold finance, legal, clinical, or industry expertise but lack someone who can connect product reality to commercial adoption, regulatory exposure, and operating execution. That translation is my native language.
Generalist investors often can't assess linked product, regulatory, AI, security, and commercialization risk, and portfolio companies stall after investment because those issues never became an operating plan. I support investors and portfolio companies where these dimensions are tightly coupled, including diligence work for a healthtech investment fund.
I am most useful to boards of growth-stage, investor-backed, or strategically important technical companies where product, AI, regulation, quality, security, and enterprise adoption are tightly linked.
I am especially useful where the board needs an operator who can translate technical reality into commercial, regulatory, and governance implications.
18+ years as an operator in regulated healthtech, including 5+ as VP, spanning early-stage build-and-scale roles and Fortune 500 institutional scale with M&A integration. 30+ regulated AI-enabled products launched, supporting more than $2B in revenue.
Founder of Vahana Labs. Board member at Red Dot Ranch, a climate-tech potable water company. Illumyn Boardroom Excellence Fellow. Diligence team member at NDVC. Advisor and mentor at Alchemist Accelerator, Redesign Health, The Batchery, and Plug and Play MedTech. Former Treasurer and Audit Committee member, ASQ Biomedical Division.
Babson MBA, CMU CDAIO, RAC (Devices), CISM, CIPM, CIPP (US and EU), CSQE.
Co-author of Built to Survive: Building Trusted AI Products and Organizations, expected fall 2026.
Tell me about the company and the gap you are trying to close. I will tell you honestly whether I am the right fit.
Or write directly: arvita@vahanalabs.ai